ZAI LAB (09688.HK) -0.360 (-2.332%) Short selling $35.31M; Ratio 29.188% (Zai Lab Limited (ZLAB.US) ) announced its first-quarter results. Under US GAAP, total revenue declined 6.5% YoY to USD99.61 million, mainly due to certain competitive impacts on ZEJULA and price adjustments related to NUZYRA's renewal under the National Reimbursement Drug List. Net loss widened to USD51.02 million from USD48.44 million in the same period last year, attributable to lower product revenue and increased research and development expenses, partly offset by foreign exchange gains. LPS was USD0.05. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)
AASTOCKS Financial News